{"hands_on_practices": [{"introduction": "Managing classical trigeminal neuralgia often begins with carbamazepine, a highly effective medication. However, its use is moderated by the risk of severe cutaneous adverse reactions, a risk strongly linked to a patient's genetic makeup. This exercise [@problem_id:4532577] delves into the crucial intersection of pharmacogenomics, immunology, and clinical epidemiology, challenging you to apply first principles to understand the mechanism of this adverse reaction and to quantify the public health benefit of a preemptive screening program.", "problem": "A patient aged $58$ years presents with classical trigeminal neuralgia and is being evaluated for pharmacologic therapy. Carbamazepine is considered first-line, but the clinician is aware of the association between the human leukocyte antigen (HLA) allele HLA-B*15:02 and carbamazepine-induced Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), particularly in individuals of certain Asian ancestries. The health system is considering a policy to screen all patients self-identifying as East or South Asian ancestries for HLA-B*15:02 before initiating carbamazepine. Positive individuals would avoid carbamazepine and be managed with alternative agents (for example, baclofen or lamotrigine) or earlier surgical options (for example, microvascular decompression) when medically appropriate.\n\nUse the following scientifically plausible parameters for a population of new carbamazepine users with East or South Asian ancestry:\n- HLA-B*15:02 carrier prevalence $p = 0.10$.\n- Incidence of carbamazepine-induced SJS/TEN among HLA-B*15:02 carriers $I_{c} = 1.0\\%$.\n- Incidence of carbamazepine-induced SJS/TEN among non-carriers $I_{n} = 0.02\\%$.\n- Assume that individuals who test positive for HLA-B*15:02 do not receive carbamazepine and that the alternative regimens chosen for them have negligible risk of SJS/TEN in this context.\n\nFrom first principles of immunogenetics and clinical epidemiology, explain the rationale for ancestry-informed HLA-B*15:02 testing before carbamazepine initiation, and estimate the absolute risk reduction achieved by screening in this at-risk population. Choose the single best option that correctly states both the mechanistic rationale and the quantitative estimate.\n\nA. HLA-B*15:02 encodes a major histocompatibility complex class I molecule that can present carbamazepine (or its intermediates) directly to cytotoxic T cells, triggering keratinocyte apoptosis and SJS/TEN in a strongly allele-restricted manner. Because the allele is enriched in East and South Asian populations, ancestry-informed preemptive testing identifies patients at markedly increased risk; avoiding carbamazepine in carriers reduces the population incidence from $p I_{c} + (1-p) I_{n} = 0.10 \\times 1.0\\% + 0.90 \\times 0.02\\% = 0.118\\%$ to $(1-p) I_{n} = 0.90 \\times 0.02\\% = 0.018\\%$, yielding an absolute risk reduction of $0.100\\%$ (approximately $1$ per $1000$).\n\nB. HLA-A*31:01 testing should be performed universally irrespective of ancestry because it predicts carbamazepine-induced SJS/TEN; the absolute risk reduction equals the baseline incidence $0.118\\%$.\n\nC. Carbamazepine-induced SJS/TEN risk is not mediated by HLA alleles but by nonspecific metabolite toxicity; therefore, ancestry-based HLA screening confers no benefit, and the absolute risk reduction is $0\\%$.\n\nD. Ancestry-informed screening for HLA-B*15:02 in East and South Asians is justified, but the absolute risk reduction equals the post-screening incidence $0.018\\%$ rather than a larger value.\n\nE. The principal utility of HLA-B*15:02 testing in trigeminal neuralgia is to predict maculopapular exanthema rather than SJS/TEN; carriers should be switched to oxcarbazepine, and the screening reduces absolute risk by $0.50\\%$.", "solution": "The problem statement is assessed to be valid. It is scientifically grounded in established principles of pharmacogenomics and clinical epidemiology, well-posed with sufficient data for a unique solution, and objectively phrased.\n\nThe problem asks for two components: the scientific rationale for ancestry-informed HLA-B*15:02 testing before initiating carbamazepine, and the quantitative estimation of the absolute risk reduction (ARR) achieved by this screening policy in the specified at-risk population.\n\n**1. Scientific Rationale**\n\nThe rationale is based on the intersection of immunogenetics, pharmacology, and population genetics.\n- **Immunogenetic Mechanism:** The human leukocyte antigen (HLA) system encodes for major histocompatibility complex (MHC) proteins. Specifically, HLA-B alleles encode MHC class I molecules, which are expressed on the surface of most nucleated cells. Their physiological function is to present endogenous peptide fragments to cytotoxic T-lymphocytes (CD8+ T cells), a key step in immune surveillance. In the case of carbamazepine-induced Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the HLA-B*15:02 protein product has a specific binding pocket that is thought to non-covalently bind carbamazepine or its metabolites. This drug-MHC complex is recognized by T-cell receptors on cytotoxic T-lymphocytes, triggering a massive, aberrant immune cascade. This results in widespread apoptosis (programmed cell death) of keratinocytes in the skin and mucous membranes, which is the pathological hallmark of SJS/TEN. This is a classic example of a T-cell-mediated, allele-restricted, severe cutaneous adverse drug reaction.\n- **Population Genetics:** The prevalence of the HLA-B*15:02 allele is not uniform across global populations. It is found at a significantly higher frequency in individuals of East and South Asian ancestry (often $5\\%$-$15\\%$) compared to its near-absence in European and African populations.\n- **Clinical Application:** The combination of a strong, specific genetic association and a high allele frequency in a defined population makes targeted, pre-emptive genetic screening a clinically effective and cost-effective strategy. By identifying carriers of HLA-B*15:02 before they are exposed to carbamazepine, clinicians can prevent a predictable, life-threatening adverse event.\n\n**2. Quantitative Analysis: Absolute Risk Reduction (ARR)**\n\nAbsolute Risk Reduction is defined as the difference between the event rate in the control group (no screening) and the event rate in the intervention group (with screening).\n\n$$ARR = \\text{Risk}_{\\text{baseline}} - \\text{Risk}_{\\text{post-screening}}$$\n\nThe givens are:\n- Prevalence of HLA-B*15:02 carriers: $p = 0.10$\n- Proportion of non-carriers: $1 - p = 1 - 0.10 = 0.90$\n- Incidence of SJS/TEN in carriers: $I_{c} = 1.0\\% = 0.01$\n- Incidence of SJS/TEN in non-carriers: $I_{n} = 0.02\\% = 0.0002$\n\n**Step 2.1: Calculate Baseline Risk (without screening)**\n\nWithout screening, the entire population is treated with carbamazepine. The overall incidence is the weighted average of the incidences in the carrier and non-carrier subgroups, determined by the law of total probability.\n\n$$ \\text{Risk}_{\\text{baseline}} = (p \\times I_{c}) + ((1-p) \\times I_{n}) $$\n$$ \\text{Risk}_{\\text{baseline}} = (0.10 \\times 1.0\\%) + (0.90 \\times 0.02\\%) $$\n$$ \\text{Risk}_{\\text{baseline}} = 0.10\\% + 0.018\\% $$\n$$ \\text{Risk}_{\\text{baseline}} = 0.118\\% $$\n\n**Step 2.2: Calculate Post-Screening Risk (with screening)**\n\nWith the screening policy, carriers ($10\\%$ of the population) are identified and not given carbamazepine. The problem states their alternative therapy has negligible risk, so their contribution to the SJS/TEN incidence is $0$. The non-carriers ($90\\%$ of the population) are given carbamazepine and have an incidence of $I_{n}$.\n\nThe overall incidence in the population is now calculated based on this new reality. The cases of SJS/TEN will only occur within the non-carrier group.\n\n$$ \\text{Risk}_{\\text{post-screening}} = (p \\times 0) + ((1-p) \\times I_{n}) $$\n$$ \\text{Risk}_{\\text{post-screening}} = 0 + (0.90 \\times 0.02\\%) $$\n$$ \\text{Risk}_{\\text{post-screening}} = 0.018\\% $$\n\n**Step 2.3: Calculate Absolute Risk Reduction (ARR)**\n\n$$ ARR = \\text{Risk}_{\\text{baseline}} - \\text{Risk}_{\\text{post-screening}} $$\n$$ ARR = 0.118\\% - 0.018\\% $$\n$$ ARR = 0.100\\% $$\n\nAn ARR of $0.100\\%$ means that for every $1000$ individuals from this at-risk population who are screened, $1$ case of SJS/TEN is prevented ($0.100\\% = 0.100/100 = 1/1000$). Alternatively, the ARR is equal to the risk contributed by the group in which the intervention is effective, which is the risk in carriers that is now avoided: $p \\times I_c = 0.10 \\times 1.0\\% = 0.10\\%$.\n\n**Evaluation of Options**\n\n*   **A. HLA-B*15:02 encodes a major histocompatibility complex class I molecule that can present carbamazepine (or its intermediates) directly to cytotoxic T cells, triggering keratinocyte apoptosis and SJS/TEN in a strongly allele-restricted manner. Because the allele is enriched in East and South Asian populations, ancestry-informed preemptive testing identifies patients at markedly increased risk; avoiding carbamazepine in carriers reduces the population incidence from $p I_{c} + (1-p) I_{n} = 0.10 \\times 1.0\\% + 0.90 \\times 0.02\\% = 0.118\\%$ to $(1-p) I_{n} = 0.90 \\times 0.02\\% = 0.018\\%$, yielding an absolute risk reduction of $0.100\\%$ (approximately $1$ per $1000$).**\n    - The mechanistic rationale is accurate.\n    - The calculation of baseline risk ($0.118\\%$), post-screening risk ($0.018\\%$), and absolute risk reduction ($0.100\\%$) is arithmetically and conceptually correct.\n    - **Verdict: Correct.**\n\n*   **B. HLA-A*31:01 testing should be performed universally irrespective of ancestry because it predicts carbamazepine-induced SJS/TEN; the absolute risk reduction equals the baseline incidence $0.118\\%$.**\n    - This option discusses HLA-A*31:01, which, while relevant for carbamazepine hypersensitivity in some populations (e.g., Europeans), is not the allele specified in the problem's context for East and South Asians, where HLA-B*15:02 is the primary concern for SJS/TEN.\n    - The claim that ARR equals the baseline incidence is false. This would imply a post-screening risk of $0$, which is incorrect as non-carriers still have a residual risk ($I_{n} > 0$).\n    - **Verdict: Incorrect.**\n\n*   **C. Carbamazepine-induced SJS/TEN risk is not mediated by HLA alleles but by nonspecific metabolite toxicity; therefore, ancestry-based HLA screening confers no benefit, and the absolute risk reduction is $0\\%$.**\n    - The premise is factually incorrect. The strong, specific association with HLA-B*15:02 is one of the most robust findings in pharmacogenomics. Denying this HLA-mediated mechanism is contrary to established scientific fact.\n    - Consequently, the conclusion that screening has no benefit (ARR = $0\\%$) is also incorrect.\n    - **Verdict: Incorrect.**\n\n*   **D. Ancestry-informed screening for HLA-B*15:02 in East and South Asians is justified, but the absolute risk reduction equals the post-screening incidence $0.018\\%$ rather than a larger value.**\n    - This option correctly justifies the screening but misunderstands the definition of absolute risk reduction. ARR is the *difference* in risk ($0.100\\%$), not the final, post-intervention risk ($0.018\\%$).\n    - **Verdict: Incorrect.**\n\n*   **E. The principal utility of HLA-B*15:02 testing in trigeminal neuralgia is to predict maculopapular exanthema rather than SJS/TEN; carriers should be switched to oxcarbazepine, and the screening reduces absolute risk by $0.50\\%$.**\n    - This option contains multiple errors. The primary utility of HLA-B*15:02 testing is to prevent the life-threatening SJS/TEN, not the milder maculopapular exanthema.\n    - Recommending oxcarbazepine for an HLA-B*15:02 carrier is dangerous advice due to significant cross-reactivity and risk of SJS/TEN.\n    - The calculated ARR of $0.50\\%$ is incorrect; the correct value is $0.100\\%$.\n    - **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4532577"}, {"introduction": "When medical management fails or is poorly tolerated, neurosurgical or percutaneous procedures targeting the trigeminal nerve offer significant relief. These powerful interventions, however, require a deep appreciation for functional neuroanatomy, as unintended injury to adjacent structures can lead to new, permanent deficits. This practice problem [@problem_id:4532580] uses the classic corneal blink reflex as a model to hone your clinical reasoning, tasking you with predicting the precise neurological consequences of a procedural complication based on the fundamental wiring of the brainstem.", "problem": "A patient with classic right-sided trigeminal neuralgia confined to the maxillary division undergoes percutaneous radiofrequency thermocoagulation (RFTC) of the trigeminal (Gasserian) ganglion. Post-procedure, the patient reports diminished corneal sensation and numbness over the right forehead, consistent with unintended partial injury to the ophthalmic division ($V_{1}$). Gamma Knife radiosurgery (GKRS) targeting the trigeminal root entry zone can produce a similar pattern of sensory change if dose fall-off extends to $V_{1}$ afferents. From the first-principles definition of a brainstem reflex arc (receptor, afferent limb, central interneurons, efferent limb, effector), consider the corneal blink reflex as a nociceptive reflex initiated by corneal free nerve endings. Using only this framework and core neuroanatomy, predict the specific corneal reflex findings when each cornea is lightly touched with a cotton wisp and the most likely ocular complication of the documented right $V_{1}$ sensory impairment.\n\nWhich option best matches the expected findings and complication?\n\nA. Touching the right cornea evokes no blink in either eye; touching the left cornea evokes bilateral blinks. The major ocular risk is neurotrophic keratopathy of the right cornea due to loss of trophic afferent input, with preserved facial motor output.\n\nB. Touching the right cornea evokes no blink on the right but a consensual blink on the left; touching the left cornea evokes a direct blink on the left but no consensual blink on the right. The major ocular risk is exposure keratopathy from orbicularis oculi weakness.\n\nC. Touching the right cornea evokes a direct blink on the right but no consensual blink on the left; touching the left cornea evokes no blink in either eye. The major ocular risk is reflex hyperlacrimation preventing corneal injury.\n\nD. Touching either cornea evokes no blink in either eye. The major ocular risk is due to bilateral facial nucleus dysfunction rather than primary sensory denervation.\n\nE. Touching the right cornea evokes delayed bilateral blinks; touching the left cornea evokes normal bilateral blinks. The major ocular risk is reduced because decreased nociception lowers mechanical trauma to the epithelium.", "solution": "The problem requires a prediction of clinical findings based on a specific iatrogenic neurological injury, using the fundamental principles of a brainstem reflex arc and core neuroanatomy.\n\n### Step 1: Validation of the Problem Statement\n\n**1. Extraction of Givens:**\n- **Patient Condition:** Classic right-sided trigeminal neuralgia, confined to the maxillary division ($V_{2}$).\n- **Procedure:** Percutaneous radiofrequency thermocoagulation (RFTC) of the right trigeminal (Gasserian) ganglion.\n- **Post-procedural Finding:** Unintended partial injury to the ophthalmic division ($V_{1}$) on the right side.\n- **Clinical Signs of Injury:** Diminished corneal sensation and numbness over the right forehead.\n- **Analytical Framework:** The first-principles definition of a brainstem reflex arc: receptor, afferent limb, central interneurons, efferent limb, effector.\n- **Specific Reflex:** The corneal blink reflex, defined as a nociceptive reflex.\n- **Question:** Predict the findings of the corneal reflex test and identify the most likely ocular complication from the right $V_{1}$ sensory impairment.\n\n**2. Validation Analysis:**\n- **Scientific Grounding:** The problem is firmly grounded in established principles of clinical neuroanatomy and neurophysiology. The anatomical structures (trigeminal nerve and its divisions $V_{1}, V_{2}, V_{3}$; facial nerve $CN\\ VII$; trigeminal ganglion; brainstem nuclei) and their functions are standard medical knowledge. The corneal blink reflex is a canonical example of a brainstem reflex. The procedure (RFTC) and its potential complications (sensory loss in adjacent nerve divisions) are clinically realistic. The complication of neurotrophic keratopathy following corneal denervation is a well-documented pathological entity.\n- **Well-Posedness:** The problem provides a clear and specific clinical scenario (a right-sided $V_{1}$ afferent lesion with intact motor pathways) and asks for a prediction of two related outcomes (reflex response and long-term complication). The analytical framework is explicitly defined. A unique and logical solution can be derived from the provided information.\n- **Objectivity:** The problem statement is objective, using precise medical terminology. It is free of ambiguity, subjectivity, or opinion.\n\n**3. Verdict:**\nThe problem statement is valid. It is scientifically sound, well-posed, unambiguous, and based on established medical science. I will proceed with the derivation of the solution.\n\n### Step 2: Derivation of the Solution\n\n**Principle-Based Derivation of Corneal Reflex Findings**\n\nThe corneal blink reflex arc is analyzed component by component:\n1.  **Receptor:** Nociceptive free nerve endings in the corneal stroma and epithelium.\n2.  **Afferent Limb:** Sensory fibers of the ophthalmic division ($V_{1}$) of the trigeminal nerve ($CN\\ V$). Their cell bodies reside in the trigeminal ganglion, and their central axons synapse in the spinal trigeminal nucleus in the pons and medulla.\n3.  **Central Interneurons:** Neurons originating in the spinal trigeminal nucleus project to the facial motor nuclei ($CN\\ VII$ nucleus) *bilaterally*. This bilateral connection is a critical feature, ensuring that a unilateral stimulus normally produces a bilateral response.\n4.  **Efferent Limb:** Motor fibers of the facial nerve ($CN\\ VII$), which arise from the facial motor nucleus in the pons.\n5.  **Effector:** The orbicularis oculi muscle, innervated by the facial nerve, which contracts to close the eyelid (blink).\n\nThe problem specifies an injury to the **right ophthalmic division ($V_{1}$)**. This constitutes a lesion of the afferent limb of the reflex arc for the right eye. The procedure (RFTC of the trigeminal ganglion) does not typically affect the facial nerve or its nucleus. Therefore, we must assume the efferent pathways (left and right $CN\\ VII$) and the afferent pathway from the left eye (left $V_{1}$) are intact.\n\nLet us test the reflex by stimulating each cornea:\n-   **Touching the right cornea:** The stimulus is applied to a cornea with diminished sensation. The afferent signal travelling along the right $V_{1}$ is blocked or severely attenuated. Consequently, the signal fails to reach the spinal trigeminal nucleus in the brainstem. Since the central processing portion of the arc is not activated, no signal is transmitted via interneurons to either the ipsilateral or contralateral facial motor nucleus.\n    - **Result:** No firing of the right or left facial nerve. No contraction of the right or left orbicularis oculi. This means **no blink in either eye**.\n\n-   **Touching the left cornea:** The stimulus is applied to a normally innervated cornea. The afferent signal travels uninterrupted along the left $V_{1}$ to the spinal trigeminal nucleus. From there, interneurons activate **both** the left and right facial motor nuclei. Both facial nerves fire, causing contraction of both the left and right orbicularis oculi muscles.\n    - **Result:** A direct blink in the left eye and a consensual blink in the right eye. This means **a bilateral blink**.\n\n**Principle-Based Derivation of the Ocular Complication**\n\nThe trigeminal innervation of the cornea serves two functions: sensation (nociception, touch, temperature) and trophic support. The term 'trophic' refers to the nerve's role in regulating the metabolism, proliferation, and healing of the corneal epithelial and stromal cells.\n-   **The Injury:** The documented right $V_{1}$ sensory impairment signifies a loss of this sensory and trophic innervation to the right cornea.\n-   **Consequence 1 (Loss of Protection):** The absence of sensation means the patient will not feel foreign bodies, abrasions, or other injuries to the cornea, preventing the protective blink reflex and conscious avoidance behaviors.\n-   **Consequence 2 (Loss of Trophic Support):** The loss of nerve-derived growth factors and neuropeptides impairs the health of the corneal epithelium. This leads to reduced cell adhesion, decreased mitotic rate, and impaired wound healing. The epithelium can break down spontaneously, leading to persistent epithelial defects.\n-   **The Pathology:** This condition is known as **neurotrophic keratopathy** (or neurotrophic keratitis). It is a degenerative corneal disease caused by impaired corneal innervation. If untreated, it can progress to ulceration, melting, and perforation of the cornea, potentially leading to vision loss.\n-   **Distinction from Exposure Keratopathy:** The facial motor output is preserved, as the lesion is in $CN\\ V$, not $CN\\ VII$. The patient can still blink voluntarily and exhibits a consensual blink in the right eye upon left corneal stimulation. Therefore, the cornea is not suffering from exposure due to an inability to close the eye, which is the definition of exposure keratopathy.\n\n### Step 3: Option-by-Option Analysis\n\n**A. Touching the right cornea evokes no blink in either eye; touching the left cornea evokes bilateral blinks. The major ocular risk is neurotrophic keratopathy of the right cornea due to loss of trophic afferent input, with preserved facial motor output.**\n- **Reflex Analysis:** This statement perfectly matches the derived findings. A right afferent lesion abolishes the reflex upon right-sided stimulation. An intact left afferent path and bilateral central/efferent paths produce a bilateral blink upon left-sided stimulation.\n- **Complication Analysis:** This correctly identifies neurotrophic keratopathy as the complication, correctly attributes it to the loss of trophic afferent input, and correctly notes the preservation of facial motor output.\n- **Verdict:** **Correct**.\n\n**B. Touching the right cornea evokes no blink on the right but a consensual blink on the left; touching the left cornea evokes a direct blink on the left but no consensual blink on the right. The major ocular risk is exposure keratopathy from orbicularis oculi weakness.**\n- **Reflex Analysis:** This pattern (\"no consensual blink on the right\") describes a right-sided facial nerve ($CN\\ VII$) palsy, i.e., an efferent lesion. The described injury is afferent ($V_{1}$). The first part (\"no blink on the right but a consensual blink on the left\" from a right stimulus) is physiologically impossible for a single lesion.\n- **Complication Analysis:** This incorrectly identifies exposure keratopathy, which results from a motor ($CN\\ VII$) deficit, not the sensory ($V_{1}$) deficit described.\n- **Verdict:** **Incorrect**.\n\n**C. Touching the right cornea evokes a direct blink on the right but no consensual blink on the left; touching the left cornea evokes no blink in either eye. The major ocular risk is reflex hyperlacrimation preventing corneal injury.**\n- **Reflex Analysis:** This pattern is inconsistent with the given lesion. \"Touching the left cornea evokes no blink\" would imply a left afferent lesion, which is not stated. \"Direct blink on the right but no consensual on the left\" is also inconsistent with the central bilateral pathways of the reflex.\n- **Complication Analysis:** Reflex hyperlacrimation is not the characteristic outcome; in fact, damage to parasympathetic fibers that travel with $CN\\ V$ can lead to dry eye. The primary risk is corneal tissue degeneration, not something prevented by lacrimation.\n- **Verdict:** **Incorrect**.\n\n**D. Touching either cornea evokes no blink in either eye. The major ocular risk is due to bilateral facial nucleus dysfunction rather than primary sensory denervation.**\n- **Reflex Analysis:** The absence of a blink from stimulating the left cornea is incorrect; the left afferent pathway is intact.\n- **Complication Analysis:** Attributing the risk to bilateral facial nucleus dysfunction contradicts the problem, which localizes the injury to the right trigeminal ganglion and resulting $V_{1}$ deficit.\n- **Verdict:** **Incorrect**.\n\n**E. Touching the right cornea evokes delayed bilateral blinks; touching the left cornea evokes normal bilateral blinks. The major ocular risk is reduced because decreased nociception lowers mechanical trauma to the epithelium.**\n- **Reflex Analysis:** \"Diminished sensation\" from a procedure like RFTC, which creates a thermal lesion, implies axonal damage and signal block, leading to an absent, not a delayed, reflex.\n- **Complication Analysis:** This conclusion is fundamentally wrong and dangerous. The loss of protective sensation and trophic support dramatically *increases* the risk of corneal injury and disease. The claim that the risk is \"reduced\" is the opposite of the truth.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4532580"}, {"introduction": "A central question in the long-term management of trigeminal neuralgia is the comparative effectiveness of medical versus surgical therapy. Clinicians and patients must weigh the convenience and risks of lifelong medication against the higher upfront risk and potentially greater efficacy of surgery. This exercise [@problem_id:4532651] provides a direct, hands-on application of evidence-based medicine by asking you to transform raw outcome data from a hypothetical clinical trial into the Number Needed to Treat (NNT), an intuitive and powerful metric for comparing therapeutic strategies.", "problem": "A randomized comparative effectiveness study enrolled patients with classic trigeminal neuralgia undergoing either early microvascular decompression (MVD) or optimized carbamazepine (CBZ) monotherapy. The primary unfavorable outcome was prespecified as persistent, disabling facial pain at $12$ months, adjudicated by blinded assessors using standardized criteria. Suppose there was no loss to follow-up and no censoring, and the outcomes were independent across participants.\n\nAt $12$ months, the CBZ arm had $155$ participants with the unfavorable outcome out of $250$ randomized, while the MVD arm had $40$ participants with the unfavorable outcome out of $220$ randomized.\n\nUsing only core definitions of risk (proportion with the event), absolute risk reduction, and number needed to treat, compute the number needed to treat to prevent one case of persistent disabling pain at $12$ months when treating with MVD rather than CBZ. Treat CBZ as the comparator (control) and MVD as the intervention, and interpret the unfavorable outcome as the event. Report the number needed to treat as a pure number (no units) and round your final answer to three significant figures.", "solution": "We begin from core definitions:\n\n1. For each arm, the risk (event rate) is the proportion of participants experiencing the unfavorable event over the follow-up interval. If $x$ is the number of events and $n$ is the number randomized, then the risk is $p = x/n$.\n\n2. The absolute risk reduction (ARR) for an intervention that reduces an unfavorable event is the difference between the control risk and the intervention risk:\n$$\n\\text{ARR} = p_{\\text{control}} - p_{\\text{intervention}}.\n$$\n\n3. The number needed to treat (NNT) to prevent one event is the reciprocal of the absolute risk reduction:\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}}.\n$$\n\nWe now compute the risks.\n\n- Control (CBZ) risk:\n$$\np_{\\text{CBZ}} = \\frac{155}{250} = \\frac{31}{50} = 0.62.\n$$\n\n- Intervention (MVD) risk:\n$$\np_{\\text{MVD}} = \\frac{40}{220} = \\frac{4}{22} = \\frac{2}{11} \\approx 0.181818\\ldots\n$$\n\nCompute the absolute risk reduction:\n$$\n\\text{ARR} = p_{\\text{CBZ}} - p_{\\text{MVD}} = \\frac{31}{50} - \\frac{2}{11}.\n$$\nBring to a common denominator:\n$$\n\\frac{31}{50} - \\frac{2}{11} = \\frac{31 \\times 11}{50 \\times 11} - \\frac{2 \\times 50}{11 \\times 50} = \\frac{341}{550} - \\frac{100}{550} = \\frac{241}{550}.\n$$\n\nThus,\n$$\n\\text{ARR} = \\frac{241}{550} \\approx 0.4381818\\ldots\n$$\n\nThe number needed to treat is\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}} = \\frac{1}{241/550} = \\frac{550}{241} \\approx 2.28215\\ldots\n$$\n\nRounded to three significant figures, the NNT is\n$$\n2.28.\n$$\n\nPer the instruction, we report the NNT as a pure number with no units.", "answer": "$$\\boxed{2.28}$$", "id": "4532651"}]}